Merger Announced
NextCure and Avere Therapeutics merger
Announced 14 Jul 2026
Advisers
Avere Therapeutics
Target
- Financial adviser
- Legal adviser
Investor
- Legal adviser
Other advisers
- Legal adviser
- Target
- Avere Therapeutics
- Acquirer
- NextCure
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- Leyden Labs acquisition of RIGImmune Sep 2026 · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Novo Nordisk stake in Orbis Medicines Sep 2026 · Biotech
- Eli Lilly and Company acquisition of Merida Biosciences Aug 2026 · US$2.9bn · Biotech
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
Competing proposals
Sources
- 14 Jul 2026 Press release (GlobeNewswire), NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy globenewswire.com
- 15 Jul 2026 S&C Advises Hansoh Pharma on Exclusive License Agreement and Strategic Investment with Avere Therapeutics sullcrom.com
- 17 Jul 2026 Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private Placement sidley.com
- 20 Jul 2026 Gibson Dunn Advises Avere Therapeutics on Reverse Merger with NextCure, and Concurrent Private Financing gibsondunn.com


